Human clinical trials in Brazil for a potential coronavirus vaccine developed by Oxford University started this weekend, sponsor Lemann Foundation said in a statement late on Monday.
Trials will count on 2,000 health worker volunteers in Sao Paulo and 1,000 people in Rio de Janeiro and are being conducted by Universidade Federal de Sao Paulo and hospital chain Rede D'Or, respectively.
For more coronavirus news, visit our dedicated page.
Brazil’s health regulator Anvisa approved human clinical trials for the potential vaccine, developed by Oxford and supported by AstraZeneca Plc, earlier in June.
Brazil, where the disease is still rife, is the first country outside the United Kingdom to start testing the Oxford vaccine.
Read more: Worldwide coronavirus death toll surpasses 470,000
Researchers expect to launch the vaccine by year-end.
For all the latest headlines follow our Google News channel online or via the app
Also Read
-
EU leaders to hold two-day summit next month on virus recovery package
The leaders of the 27 EU member states will meet in Brussels on July 17, their first physical summit since the coronavirus lockdown began, to discuss ... Coronavirus -
Worldwide coronavirus death toll surpasses 470,000
The novel coronavirus has killed at least 472,173 people since the outbreak emerged in China last December, according to a tally from official sources ... Coronavirus -
Coronavirus: Brazil passes 50,000 deaths from COVID-19
Brazil on Sunday said it had registered more than 50,000 deaths from the coronavirus outbreak as well as about one million infections, as the second ... Coronavirus -
Brazil coronavirus data scandal deepens with politicians calling for probe
Brazil drew further criticism for its handling of the coronavirus pandemic on Monday after it published contradictory figures on fatalities and ... Coronavirus -
Brazil surpasses bleak milestone of one million coronavirus cases
Brazil passed the bleak milestone of one million coronavirus cases Friday, reporting a new one-day record number of infections as the pandemic ... Coronavirus
